Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside.
Morbidities of aging and Alzheimer's disease (AD) have been related to defective functions of both T cells and macrophages leading to brain amyloidosis and inflammation. In AD patients, "inflammaging" may be associated with an increase of incompetent memory T cells and inflammatory cytokines produced by macrophages, whereas defective clearance of amyloid-beta 1-42 (Abeta) may be related to defective transcription of immune genes necessary for Abeta phagocytosis, beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase and Toll-like receptors. However, AD shows considerable heterogeneity of disease manifestations and mechanisms. The approaches to re-balancing Abeta immunity and inflammation are being pursued in transgenic animal models and peripheral blood mononuclear cells of patients. The regulatory signaling pathways of microglial phagocytosis and inflammation involving co-receptors and transforming growth factor-beta have been considerably clarified in animal studies. Natural immunostimulating therapies using vitamin D3 and curcuminoids have been developed in macrophages of AD patients. AD patients possess two types of macrophages: a majority has "Type I", which are improved by curcuminoids and vitamin D3; whereas a minority has "Type II" responding positively to vitamin D3 but not to curcuminoids. Other nutritional substances, such as plant polyphenols and omega-3 fatty acids, may inhibit inflammation and stimulate immunity. More invasive immune approaches involve Abeta vaccine and cytokine antagonists. Increased inflammation may represent the "first hit", and defective transcription of immune genes the "second hit" in the pathogenesis of AD.
Fiala
Milan
M
Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA. fiala@mednet.ucla.edu
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000187:drug effects* / Q000276:immunology*; D000818:Animals; D002762:Cholecalciferol / Q000494:pharmacology / Q000627:therapeutic use; D003474:Curcumin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004660:Encephalitis / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000378:metabolism
D000276:Adjuvants, Immunologic; D016229:Amyloid beta-Peptides; D016212:Transforming Growth Factor beta; D002762:Cholecalciferol; D003474:Curcumin